Symbols / SRNE $0.00 +33.33% Sorrento Therapeutics, Inc.

Healthcare • Biotechnology • United States • PNK
SRNE Chart
About

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic test solutions, such as COVISTIX, COVITRACK, and Virex. Its products are used for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases treatment. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 1.76M
Enterprise Value 135.86M Income -548.00M Sales 64.27M
Book/sh -0.38 Cash/sh 0.15 Dividend Yield —
Payout 0.00% Employees 949 IPO —
P/E — Forward P/E — PEG —
P/S 0.03 P/B -0.01 P/C —
EV/EBITDA -0.40 EV/Sales 2.11 Quick Ratio 0.34
Current Ratio 0.41 Debt/Eq — LT Debt/Eq —
EPS (ttm) -0.55 EPS next Y — EPS Growth —
Revenue Growth 31.10% Earnings 2023-05-15 15:00 ROA -40.81%
ROE — ROIC — Gross Margin -245.01%
Oper. Margin -5.11% Profit Margin 0.00% Shs Outstand 551.28M
Shs Float 539.11M Short Float 11.96% Short Ratio 4.96
Short Interest — 52W High 0.10 52W Low 0.00
Beta 1.57 Avg Volume 148.92K Volume 501.68K
Target Price — Recom None Prev Close $0.00
Price $0.00 Change 33.33%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-1.88
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2022-12-31 2021-12-31
Total Revenue
62.84
+18.78%
52.90
Operating Revenue
62.84
+18.78%
52.90
Cost Of Revenue
33.45
+156.71%
13.03
Reconciled Cost Of Revenue
24.53
+420.96%
4.71
Gross Profit
29.39
-26.30%
39.87
Operating Expense
407.89
-0.01%
407.92
Research And Development
221.23
+6.91%
206.92
Selling General And Administration
182.34
-7.38%
196.86
Total Expenses
441.34
+4.84%
420.95
Operating Income
-378.50
-2.84%
-368.05
Total Operating Income As Reported
-504.31
-25.62%
-401.45
EBITDA
-539.93
-22.75%
-439.84
Normalized EBITDA
-364.52
+5.18%
-384.43
Reconciled Depreciation
13.24
+6.28%
12.46
EBIT
-553.17
-22.30%
-452.30
Total Unusual Items
-175.41
-216.54%
-55.41
Total Unusual Items Excluding Goodwill
-175.41
-216.54%
-55.41
Special Income Charges
-98.81
-146.39%
-40.10
Other Special Charges
50.02
+61.85%
30.90
Impairment Of Capital Assets
124.19
0.00
Restructuring And Mergern Acquisition
-75.40
-919.74%
9.20
Net Income
-572.84
-33.74%
-428.32
Pretax Income
-561.75
-21.45%
-462.53
Net Non Operating Interest Income Expense
-8.57
+16.14%
-10.22
Interest Expense Non Operating
8.57
-16.14%
10.22
Net Interest Income
-8.57
+16.14%
-10.22
Interest Expense
8.57
-16.14%
10.22
Other Income Expense
-174.67
-107.30%
-84.26
Other Non Operating Income Expenses
0.74
+102.55%
-28.84
Gain On Sale Of Security
-76.60
-400.25%
-15.31
Tax Provision
-2.42
+92.79%
-33.52
Tax Rate For Calcs
0.00
-94.06%
0.00
Tax Effect Of Unusual Items
-0.75
+81.21%
-4.02
Net Income Including Noncontrolling Interests
-577.76
-34.63%
-429.14
Net Income From Continuing Operation Net Minority Interest
-572.84
-33.74%
-428.32
Net Income From Continuing And Discontinued Operation
-572.84
-33.74%
-428.32
Net Income Continuous Operations
-577.76
-34.63%
-429.14
Minority Interests
4.91
+504.43%
0.81
Normalized Income
-398.19
-5.64%
-376.93
Net Income Common Stockholders
-572.84
-33.74%
-428.32
Diluted EPS
-1.37
+5.52%
-1.45
Basic EPS
-1.37
+5.52%
-1.45
Basic Average Shares
419.31
+42.25%
294.77
Diluted Average Shares
419.31
+42.25%
294.77
Diluted NI Availto Com Stockholders
-572.84
-33.74%
-428.32
Average Dilution Earnings
0.00
0.00
Amortization
4.33
+4.47%
4.14
Amortization Of Intangibles Income Statement
4.33
+4.47%
4.14
Depreciation Amortization Depletion Income Statement
4.33
+4.47%
4.14
Depreciation And Amortization In Income Statement
4.33
+4.47%
4.14
Earnings From Equity Interest Net Of Tax
-18.43
-14523.81%
-0.13
Line Item Trend 2022-12-31 2021-12-31
Total Assets
472.84
-31.95%
694.82
Current Assets
96.37
-44.29%
172.99
Cash Cash Equivalents And Short Term Investments
49.98
-60.61%
126.88
Cash And Cash Equivalents
23.63
-35.54%
36.66
Other Short Term Investments
26.34
-70.80%
90.22
Receivables
24.47
+30.75%
18.71
Accounts Receivable
24.47
+30.75%
18.71
Inventory
9.98
+23.07%
8.11
Raw Materials
6.60
+100.00%
3.30
Finished Goods
3.40
-27.66%
4.70
Prepaid Assets
8.81
-25.39%
11.80
Other Current Assets
3.14
-57.99%
7.48
Total Non Current Assets
376.47
-27.86%
521.83
Net PPE
138.44
+9.44%
126.50
Gross PPE
189.85
+11.69%
169.99
Accumulated Depreciation
-51.42
-18.23%
-43.49
Properties
0.00
0.00
Machinery Furniture Equipment
69.00
+12.37%
61.41
Construction In Progress
18.23
+131.40%
7.88
Other Properties
86.46
+1.52%
85.17
Leases
16.16
+4.05%
15.53
Goodwill And Other Intangible Assets
217.17
-35.98%
339.23
Goodwill
80.27
+0.94%
79.53
Other Intangible Assets
136.90
-47.29%
259.70
Investments And Advances
17.18
-66.50%
51.27
Long Term Equity Investment
17.18
-66.50%
51.27
Other Non Current Assets
3.69
-23.71%
4.83
Total Liabilities Net Minority Interest
494.51
-19.81%
616.69
Current Liabilities
327.92
+135.15%
139.45
Payables And Accrued Expenses
288.91
+232.49%
86.89
Payables
47.52
+73.32%
27.41
Accounts Payable
47.52
+73.32%
27.41
Current Accrued Expenses
241.39
+305.85%
59.48
Current Debt And Capital Lease Obligation
30.17
-30.68%
43.52
Current Debt
16.29
-49.07%
31.98
Other Current Borrowings
16.29
-49.07%
31.98
Current Capital Lease Obligation
13.88
+20.29%
11.54
Current Deferred Liabilities
0.65
-41.16%
1.11
Current Deferred Revenue
0.65
-41.16%
1.11
Other Current Liabilities
8.20
+3.31%
7.93
Total Non Current Liabilities Net Minority Interest
166.59
-65.09%
477.24
Long Term Debt And Capital Lease Obligation
104.34
-46.23%
194.06
Long Term Debt
19.13
-82.71%
110.63
Long Term Capital Lease Obligation
85.21
+2.13%
83.43
Non Current Deferred Liabilities
7.69
-93.66%
121.37
Non Current Deferred Revenue
7.10
-94.03%
118.94
Non Current Deferred Taxes Liabilities
0.59
-75.64%
2.43
Other Non Current Liabilities
54.26
-56.97%
126.11
Stockholders Equity
-18.61
-123.63%
78.75
Common Stock Equity
-18.61
-123.63%
78.75
Capital Stock
0.05
+62.50%
0.03
Common Stock
0.05
+62.50%
0.03
Share Issued
522.82
+62.29%
322.14
Ordinary Shares Number
515.25
+63.79%
314.57
Treasury Shares Number
7.57
+0.00%
7.57
Additional Paid In Capital
1,988.75
+31.38%
1,513.76
Retained Earnings
-1,959.45
-41.31%
-1,386.60
Gains Losses Not Affecting Retained Earnings
1.50
+46.30%
1.03
Treasury Stock
49.46
+0.00%
49.46
Minority Interest
-3.06
-394.99%
-0.62
Total Equity Gross Minority Interest
-21.67
-127.73%
78.13
Total Capitalization
0.53
-99.72%
189.38
Working Capital
-231.55
-790.45%
33.54
Invested Capital
16.81
-92.41%
221.35
Total Debt
134.50
-43.39%
237.58
Net Debt
11.78
-88.88%
105.94
Capital Lease Obligations
99.09
+4.34%
94.97
Net Tangible Assets
-235.78
+9.48%
-260.48
Tangible Book Value
-235.78
+9.48%
-260.48
Derivative Product Liabilities
0.30
-99.16%
35.70
Other Inventories
-0.02
-122.64%
0.11
Line Item Trend 2022-12-31 2021-12-31
Operating Cash Flow
-293.86
-4.27%
-281.82
Cash Flow From Continuing Operating Activities
-293.86
-4.27%
-281.82
Net Income From Continuing Operations
-577.76
-34.63%
-429.14
Depreciation Amortization Depletion
13.24
+6.28%
12.46
Depreciation
—
12.46
Depreciation And Amortization
13.24
+6.28%
12.46
Other Non Cash Items
-64.12
-204.68%
61.25
Stock Based Compensation
74.85
-17.01%
90.19
Asset Impairment Charge
124.19
0.00
Deferred Tax
-1.84
+94.89%
-35.93
Deferred Income Tax
-1.84
+94.89%
-35.93
Operating Gains Losses
68.02
+207.31%
22.13
Gain Loss On Investment Securities
76.60
+400.25%
15.31
Change In Working Capital
69.55
+2591.97%
-2.79
Change In Receivables
-5.68
-92.09%
-2.96
Changes In Account Receivables
-5.68
-92.09%
-2.96
Change In Inventory
-9.51
-51.53%
-6.28
Change In Prepaid Assets
6.80
+218.46%
-5.74
Change In Payables And Accrued Expense
191.16
+1040.71%
16.76
Change In Accrued Expense
181.29
+778.51%
20.64
Change In Payable
9.87
+354.51%
-3.88
Change In Account Payable
9.87
+354.51%
-3.88
Change In Other Working Capital
-113.22
-2375.88%
-4.57
Investing Cash Flow
-28.52
-135.72%
79.85
Cash Flow From Continuing Investing Activities
-28.52
-135.72%
79.85
Net PPE Purchase And Sale
-13.66
-53.95%
-8.87
Purchase Of PPE
-13.66
-53.95%
-8.87
Capital Expenditure
-13.66
-53.95%
-8.87
Net Investment Purchase And Sale
0.00
-100.00%
124.77
Sale Of Investment
0.00
-100.00%
124.77
Net Business Purchase And Sale
-14.86
+58.78%
-36.05
Purchase Of Business
-14.86
+58.78%
-36.05
Financing Cash Flow
311.72
+71.90%
181.33
Cash Flow From Continuing Financing Activities
311.72
+71.90%
181.33
Net Issuance Payments Of Debt
-92.24
-156.84%
-35.91
Issuance Of Debt
96.07
+93.13%
49.74
Repayment Of Debt
-188.31
-119.85%
-85.66
Long Term Debt Issuance
—
0.00
Long Term Debt Payments
-188.31
-119.85%
-85.66
Net Long Term Debt Issuance
-188.31
-119.85%
-85.66
Short Term Debt Issuance
96.07
+93.13%
49.74
Net Short Term Debt Issuance
96.07
+93.13%
49.74
Net Common Stock Issuance
402.33
+99.35%
201.82
Common Stock Payments
0.00
0.00
Repurchase Of Capital Stock
0.00
0.00
Proceeds From Stock Option Exercised
1.20
-92.23%
15.42
Net Other Financing Charges
0.43
—
Changes In Cash
-10.66
+48.37%
-20.64
Effect Of Exchange Rate Changes
-2.37
-381.61%
0.84
Beginning Cash Position
36.66
-35.06%
56.46
End Cash Position
23.63
-35.54%
36.66
Free Cash Flow
-307.51
-5.79%
-290.69
Interest Paid Supplemental Data
1.17
+10.66%
1.06
Income Tax Paid Supplemental Data
0.03
-97.58%
1.20
Common Stock Issuance
402.33
+99.35%
201.82
Earnings Losses From Equity Investments
18.43
+14523.81%
0.13
Issuance Of Capital Stock
402.33
+99.35%
201.82
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category